GlassScriptPhysician profile
Tammy M Holmes
NPI 1043527427
$6,471.59
in general payments reported to CMS, 2019-2025
27 companies · $3,493 in 2025
The $3,493 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $343 · 2024: $2,488 · 2025: $3,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,496 · Travel and Lodging: $1,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.40 |
| Travel and Lodging | $1,826.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,922.28 | 2024-2025 | Venaseal, Closurefast, Linq II |
| Boston Scientific Corporation | $1,486.44 | 2022-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $629.95 | 2022-2025 | Lifevest |
| Novo Nordisk INC | $347.39 | 2023-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $312.80 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $227.53 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $191.27 | 2023-2024 | Inpefa |
| Cvrx, INC. | $184.04 | 2025 | Barostim Neo System |
| Abbott Laboratories | $174.93 | 2023-2025 | Aveir, Triclip, Jot Dx |
| Biotronik INC. | $171.48 | 2025 | Biomonitor, Acticor 7 Vr-T Dx, Renamic Neo |
| Amgen INC. | $105.19 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $101.84 | 2023-2025 | Farxiga, Lokelma |
| United Therapeutics Corporation | $72.84 | 2024-2025 | Tyvaso, Tyvaso |
| Edwards Lifesciences Corporation | $72.70 | 2024-2025 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $71.76 | 2023-2025 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.46 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $46.68 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $43.38 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $38.11 | 2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $38.02 | 2025 | Camzyos |
| Philips North America LLC | $37.58 | 2025 | Extended Holter, Event |
| Kiniksa Pharmaceuticals International, Plc | $34.90 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $30.76 | 2025 | |
| Vital Connect, INC | $25.63 | 2025 | Vitalpatch Rtm |
| Pfizer INC. | $23.18 | 2024 | |
| Atricure, INC. | $18.01 | 2024 | |
| Irhythm Technologies, INC. | $14.44 | 2024 | Zio Monitor, Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.